Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Meropenem

FDA-approved product (injectable, injection), marketed as Meropenem, Meropenem And Sodium Chloride In Duplex Container, Merrem Iv.

Registered studies
50+
Lab records
263
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Meropenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial meningitis
  • Bacteriemia
  • Infection
  • Infectious meningitis
  • Meningitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH02

Repurposing investigation

Meropenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 16 of 17 lab records
  • E. coli: measured active in 38 of 38 lab records
  • K. pneumoniae: measured active in 172 of 208 lab records
Open Meropenem in ChEMBL Registered studies below
Show the latest 150 of 263 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Meropenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial

    NCT07820501 · start 2026-11

    Registered record
    Registry ID
    NCT07820501
    Conditions
    Hospital-acquired Pneumonia (HAP); Ventilator-Associated Pneumonia (VAP); Nosocomial Respiratory Infection; Critical Illness
    Interventions
    Resistance-Optimised Precision Dosing; Standard Care Dosing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-09
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-acquired Pneumonia (HAP); Ventilator-Associated Pneumonia (VAP); Nosocomial Respiratory Infection; Critical Illness
    InterventionResistance-Optimised Precision Dosing; Standard Care Dosing
    PhaseNot applicable
    Registry statusNot yet recruiting

  • The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

    NCT07556107 · start 2026-08-17

    Registered record
    Registry ID
    NCT07556107
    Conditions
    Infection; Acute Kidney Injury; Sepsis
    Interventions
    Piperacillin + Tazobactam; meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-08-17
    Completion
    2028-12-31
    Enrolment
    852

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Acute Kidney Injury; Sepsis
    InterventionPiperacillin + Tazobactam; meropenem
    PhasePhase 4
    Registry statusRecruiting

  • COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE

    NCT07641348 · start 2026-07-01

    Registered record
    Registry ID
    NCT07641348
    Conditions
    Typhoid Fever
    Interventions
    meropenem; Meropenem and azithromycin combination
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2027-02-01
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTyphoid Fever
    Interventionmeropenem; Meropenem and azithromycin combination
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients

    NCT07484633 · start 2026-04

    Registered record
    Registry ID
    NCT07484633
    Conditions
    Infection; Sepsis; NICU; PICU; Beta Lactams
    Interventions
    Extended infusion time of the following beta-lactam: meropenem; Short-term infusion time of the following beta-lactam: meropenem; Extended infusion time of the following beta-lactam: piperacillin/tazobactam; Extended infusion time of the following beta-lactam: cefepime; Extended infusion time of the following beta-lactam: ceftriaxone; Short-term infusion time of the following beta-lactam: piperacillin/tazobactam; Short-term infusion time of the following beta-lactam: cefepime; Short-term infusion time of the following beta-lactam: ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2028-04
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Sepsis; NICU; PICU +1 more
    InterventionExtended infusion time of the following beta-lactam: meropenem; Short-term infusion time of the following beta-lactam: meropenem; Extended infusion time of the following beta-lactam: piperacillin/tazobactam; Extended infusion time of the following beta-lactam: cefepime +4 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

    NCT07236944 · start 2025-12

    Registered record
    Registry ID
    NCT07236944
    Conditions
    Febrile Urinary Tract Infection
    Interventions
    Pivmecillinam; Standard of Care (Investigator Choice)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12
    Completion
    2029-03
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Urinary Tract Infection
    InterventionPivmecillinam; Standard of Care (Investigator Choice)
    PhasePhase 4
    Registry statusRecruiting

  • Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales

    NCT07160569 · start 2025-09-01

    Registered record
    Registry ID
    NCT07160569
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    Whole Genome Sequencing (WGS), Sequence Type Analysis (ST)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2026-08-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    InterventionWhole Genome Sequencing (WGS), Sequence Type Analysis (ST)
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children

    NCT06929702 · start 2025-07-09

    Registered record
    Registry ID
    NCT06929702
    Conditions
    Amoxicillin-clavulanate; Piperacillin-tazobactam; Meropenem
    Interventions
    Beta-lactam antibiotic; Beta-lactam model-informed precision dosing
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-09
    Completion
    2027-10-01
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmoxicillin-clavulanate; Piperacillin-tazobactam; Meropenem
    InterventionBeta-lactam antibiotic; Beta-lactam model-informed precision dosing
    PhasePhase 4
    Registry statusRecruiting

  • Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

    NCT06709521 · start 2025-02-12

    Registered record
    Registry ID
    NCT06709521
    Conditions
    Bacterial Infection
    Interventions
    Iohexol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-02-12
    Completion
    2026-07-02
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    InterventionIohexol
    PhasePhase 4
    Registry statusCompleted

  • Validation of Betalactam ML Prediction Models - TDMAide

    NCT06026852 · start 2024-09-26

    Registered record
    Registry ID
    NCT06026852
    Conditions
    Infections
    Interventions
    Prediction of plasma concentration of piperacillin-tazobactam or meropenem; Determination of plasma concentration of piperacillin-tazobactam or meropenem; Daily short questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-09-26
    Completion
    2025-05-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionPrediction of plasma concentration of piperacillin-tazobactam or meropenem; Determination of plasma concentration of piperacillin-tazobactam or meropenem; Daily short questionnaire
    PhaseNot applicable
    Registry statusUnknown

  • Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance

    NCT06293677 · start 2024-03-01

    Registered record
    Registry ID
    NCT06293677
    Conditions
    Febrile Neutropenia
    Interventions
    Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem; Standard dosages of piperacillin-tazobactam or meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-03-01
    Completion
    2026-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionDosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem; Standard dosages of piperacillin-tazobactam or meropenem
    PhasePhase 4
    Registry statusUnknown

  • Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

    NCT05925309 · start 2023-07-01

    Registered record
    Registry ID
    NCT05925309
    Conditions
    Biliary Atresia; Cholangitis; Anti-Bacterial Agents
    Interventions
    Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem; Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2029-12-31
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Atresia; Cholangitis; Anti-Bacterial Agents
    InterventionBasic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem; Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
    PhaseNot applicable
    Registry statusRecruiting

  • Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults

    NCT05893849 · start 2023-03-28

    Registered record
    Registry ID
    NCT05893849
    Conditions
    Aging
    Interventions
    Clinical probes
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-03-28
    Completion
    2024-04
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging
    InterventionClinical probes
    PhaseNot recorded
    Registry statusUnknown

  • Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria

    NCT05516433 · start 2023-01-23

    Registered record
    Registry ID
    NCT05516433
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-01-23
    Completion
    2025-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

    NCT05850871 · start 2023-01-06

    Registered record
    Registry ID
    NCT05850871
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    CAZ/AVI plus Aztreonam; Conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-06
    Completion
    2025-01-31
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    InterventionCAZ/AVI plus Aztreonam; Conventional treatment
    PhaseNot applicable
    Registry statusUnknown

  • A Pharmacokinetics Study of Meropenem and Piperacillin in Patients With Sepsis

    NCT05807217 · start 2022-10-26

    Registered record
    Registry ID
    NCT05807217
    Conditions
    Sepsis; Acute Kidney Injury
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-10-26
    Completion
    2023-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Acute Kidney Injury
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown